These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia. Han JJ Blood Res; 2023 Apr; 58(S1):S58-S65. PubMed ID: 37026381 [TBL] [Abstract][Full Text] [Related]
5. Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study. Iurlo A; Cattaneo D; Artuso S; Consonni D; Abruzzese E; Binotto G; Bocchia M; Bonifacio M; Castagnetti F; Galimberti S; Gozzini A; Iezza M; Latagliata R; Luciano L; Maggi A; Miggiano MC; Pregno P; Rege-Cambrin G; Russo S; Scortechini AR; Tafuri A; Tiribelli M; Fava C; Rosti G; Foa R; Breccia M; Saglio G Front Oncol; 2022; 12():839915. PubMed ID: 35311109 [TBL] [Abstract][Full Text] [Related]
6. Moving treatment-free remission into mainstream clinical practice in CML. Hughes TP; Ross DM Blood; 2016 Jul; 128(1):17-23. PubMed ID: 27013442 [TBL] [Abstract][Full Text] [Related]
7. Deep molecular responses for treatment-free remission in chronic myeloid leukemia. Dulucq S; Mahon FX Cancer Med; 2016 Sep; 5(9):2398-411. PubMed ID: 27367039 [TBL] [Abstract][Full Text] [Related]
8. Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial. Radich JP; Hochhaus A; Masszi T; Hellmann A; Stentoft J; Casares MTG; García-Gutiérrez JV; Conneally E; le Coutre PD; Gattermann N; Martino B; Saussele S; Giles FJ; Ross DM; Aimone P; Li S; Titorenko K; Saglio G Leukemia; 2021 May; 35(5):1344-1355. PubMed ID: 33707652 [TBL] [Abstract][Full Text] [Related]
9. A Systematic Review on Second Treatment-Free Remission (TFR) Attempt in Chronic Myeloid Leukemia (CML): Can it be Applied in Clinical Practice? Çiftçiler R; Akın MG; Erat Z; Eşkazan AE Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):8-14. PubMed ID: 36344420 [TBL] [Abstract][Full Text] [Related]
10. Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings. Cheng F; Li Q; Cui Z; Hong M; Li W; Zhang Y Front Oncol; 2023; 13():1146108. PubMed ID: 37091188 [TBL] [Abstract][Full Text] [Related]
12. Budget Impact of Treatment-Free Remission in Treating Chronic-Phase Philadelphia-Positive Chronic Myeloid Leukemia in Lebanon. Elias F; Gebran A; Said C; Beker RV; Ammar W J Glob Oncol; 2019 Jun; 5():1-7. PubMed ID: 31166826 [TBL] [Abstract][Full Text] [Related]
13. How to improve treatment-free remission eligibility in chronic myeloid leukaemia? Costa A; Breccia M Br J Haematol; 2024 Feb; 204(2):434-448. PubMed ID: 38148564 [TBL] [Abstract][Full Text] [Related]
14. Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study. Iurlo A; Cattaneo D; Consonni D; Castagnetti F; Miggiano MC; Binotto G; Bonifacio M; Rege-Cambrin G; Tiribelli M; Lunghi F; Gozzini A; Pregno P; Abruzzese E; Capodanno I; Bucelli C; Pizzuti M; Artuso S; Iezza M; Scalzulli E; La Barba G; Maggi A; Russo S; Elena C; Scortechini AR; Tafuri A; Latagliata R; Caocci G; Bocchia M; Galimberti S; Luciano L; Fava C; Foà R; Saglio G; Rosti G; Breccia M Front Pharmacol; 2023; 14():1154377. PubMed ID: 37033642 [TBL] [Abstract][Full Text] [Related]
15. Treatment Outcomes in Chronic Myeloid Leukemia: Does One Size Fit All? Garcia-Horton A; Lipton JH J Natl Compr Canc Netw; 2020 Oct; 18(10):1421-1428. PubMed ID: 33022650 [TBL] [Abstract][Full Text] [Related]
16. Treatment-Free Remission in Chronic Myeloid Leukemia: Can We Identify Prognostic Factors? Saifullah HH; Lucas CM Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439327 [TBL] [Abstract][Full Text] [Related]
17. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia. Legros L; Nicolini FE; Etienne G; Rousselot P; Rea D; Giraudier S; Guerci-Bresler A; Huguet F; Gardembas M; Escoffre M; Ianotto JC; Noël MP; Varet BR; Pagliardini T; Touitou I; Morisset S; Mahon FX; Cancer; 2017 Nov; 123(22):4403-4410. PubMed ID: 28743166 [TBL] [Abstract][Full Text] [Related]
18. Subsequent attempt tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia; a single institute experience. Ureshino H; Kamachi K; Nishioka A; Okamoto S; Katsuya H; Yoshimura M; Kubota Y; Ando T; Kimura S Hematol Oncol; 2021 Oct; 39(4):549-557. PubMed ID: 34117654 [TBL] [Abstract][Full Text] [Related]
19. Treatment-Free Remission in Chronic Myeloid Leukemia and New Approaches by Targeting Leukemia Stem Cells. Chen Y; Zou J; Cheng F; Li W Front Oncol; 2021; 11():769730. PubMed ID: 34778088 [TBL] [Abstract][Full Text] [Related]
20. De-escalation or discontinuation of tyrosine kinase inhibitor in patients with chronic myeloid leukemia: A multicentral, open-label, prospective trial in China. Luo J; Du X; Lou J; Wu J; Ma L; Huang J; Wang L; Tu C; Liu Z; Chen L; Tan Y; Luo D; Liang H; Yin C; Cao R; Zhou X; Liu Q; Liu X; Xu N EJHaem; 2022 Nov; 3(4):1220-1230. PubMed ID: 36467815 [No Abstract] [Full Text] [Related] [Next] [New Search]